10 Participants NeededMy employer runs this trial

Oral 5-ALA for Kidney Cancer

PD
Overseen ByPeace Deh, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Henry Ford Health System
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this prospective, single-arm feasibility study is to evaluate the safety and feasibility of using Gleolan® (5-aminolevulinic acid), an FDA-approved drug currently used during brain tumor surgery, in adults with suspected kidney cancer undergoing partial nephrectomy. Gleolan has shown promise in improving the visualization of cancerous tissue, and this study aims to assess its potential use in urologic oncology. The main questions it aims to answer are:

* Is Gleolan safe and well tolerated in patients with suspected kidney cancer undergoing partial nephrectomy?

* Is the use of Gleolan feasible for fluorescence-guided identification of kidney cancer lesions during surgery?

Participants will:

* Receive Gleolan before surgery according to the study protocol.

* Undergo partial nephrectomy, during which fluorescence imaging will be used to evaluate the visualization of kidney tumor tissue.

* Be monitored for safety outcomes and any adverse events before, during, and after surgery.

Who Is on the Research Team?

JR

Johar Raza, MD

Principal Investigator

Henry Ford Health

Are You a Good Fit for This Trial?

This trial is for adults with suspected kidney cancer who are scheduled to have part of their kidney removed (partial nephrectomy).

Inclusion Criteria

I am 18 years old or older.
Able to comply with study requirements
I need a partial kidney removal as part of standard treatment.
See 1 more

Exclusion Criteria

Known porphyria or hypersensitivity to porphyrins
AST or ALT greater than 2x upper limit of normal within 30 days prior to surgery
I am currently pregnant or breastfeeding.
See 2 more

What Are the Treatments Tested in This Trial?

Interventions

  • 5-Aminolevulinic acid Hydrochloride (Gliolan®)

Trial Overview

The study tests if taking Gleolan (5-ALA) by mouth before surgery helps doctors see kidney tumors better using special fluorescent imaging during the operation. All participants receive the drug and undergo this imaging.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: 5-ALA Fluorescence ImagingExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Henry Ford Health System

Lead Sponsor

Trials
334
Recruited
2,197,000+